NEW YORK (GenomeWeb News) – The Enzo Clinical Labs division of Enzo Biochem has received approval from the New York State Department of Health to market GeneNews' ColonSentry test to residents of the state.
ColonSentry is a gene expression assay for assessing a patient's risk for colorectal cancer. Enzo holds the exclusive rights to market the test in New York and New Jersey under an agreement signed in 2009.
"The New York State review process is widely regarded to be amongst the most stringent in the clinical lab industry and provides important validation for the robustness of the ColonSentry test and underlying Sentinel Principle technology," Gailina Liew, president and COO of GeneNews, said in a statement.